Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

CLL Information & Management

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with
Dr. Koffman was interviewed by Prevention magazine to share some of his emotional experiences when he was diagnosed with chronic lymphocytic leukemia in 2005 and what he learned that helped him cope, primarily through the early part of his journey when he was asked to “Watch and Wait.” The